Overview

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy and safety of a 6-month all-oral regimen including Bedaquiline (BDQ,B), Delamanid (DLM,D), Linezolid (LZD, L), and Levofloxacin (LFX,L) to the the standard long - course treatment regimen within the Chinese population. The main questions it aims to answer are: Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen? Participants will: Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned.
Phase:
NA
Details
Lead Sponsor:
Wuhan Pulmonary Hospital
Treatments:
bedaquiline
Clofazimine
Cycloserine
Levofloxacin
Linezolid
OPC-67683